Hugo surgical robot gains US clearance for general surgery
Medtronic expands the US indications for its robotic-assisted surgery platform; clearance is not proof of superior outcomes.

Medtronic has reported expanded FDA 510(k) clearance for the Hugo robotic-assisted surgery system. The decision extends its US use to general surgical procedures.
The announcement includes upper-abdominal procedures such as cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small-bowel resection. Medtronic also lists inguinal hernia repair and appendectomy. The company says these procedures account for approximately 3.5 million annual US operations: a potential field of use, not a forecast of robotic procedure volumes.
Context and evidence
The expanded regulatory scope is a concrete development for the platform. It does not by itself establish better outcomes than existing alternatives for every listed indication. The announcement concerns the United States and does not establish availability in other countries or at individual hospitals.
What it means
US hospitals can evaluate Hugo for a broader range of procedures. Practical adoption still depends on training, teams, utilization and procedure selection; clearance alone does not settle those questions.
Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.
More from Regulation
AI illustrationFDA clears AI software for coronary CT analysis
Syngo.CT Coronary Cockpit analyzes plaque and supports intervention planning. The clearance applies to the US market.
AI illustrationPhilips submits helium-free 3T MRI platform to the FDA
BlueSeal Horizon is under review, not cleared; “helium-free” describes operation with helium sealed inside the magnet.
AI illustrationFDA clears MiniMed Fit tubeless insulin pump
The company plans a phased US launch in spring 2027 following clearance for users aged seven and older.